Cetylated Fatty Acids (CFAs), such as cetyl myristoleate, have been studied primarily for their effects on joint health, particularly in the context of osteoarthritis and related musculoskeletal discomfort. There is some scientific evidence, mostly from small-scale clinical trials and animal studies, suggesting that topical or oral CFAs may support joint function and reduce stiffness, pain, and inflammation. The hypothesized mechanism of action involves the ability of CFAs to lubricate cell membranes and modulate inflammatory pathways, potentially benefiting the musculoskeletal system indirectly by improving joint mobility and reducing discomfort.

However, the direct evidence for supporting muscle tissue specifically—such as enhancing muscle strength, recovery, or growth—is limited. Most clinical research focuses on outcomes related to joint health rather than muscles per se. For example, some studies demonstrate improvements in mobility and reductions in pain for individuals with osteoarthritis, which can facilitate muscle function by enabling more comfortable movement. Still, robust, high-quality studies directly linking CFAs to muscle health are lacking.

In summary, while there is some scientific validation for the use of CFAs in supporting the broader musculoskeletal system (mainly joint health), the evidence for direct muscle support is modest and not well-established. The overall evidence rating is therefore 2 out of 5.